SPDYA (Speedy A) is a cell cycle regulator that primarily functions as a CDK activator protein. It binds and activates CDK1 and CDK2 to regulate G1/S phase transition 1, inducing conformational changes in CDK2's T-loop that facilitate substrate binding without requiring phosphorylation 2. Beyond canonical cell cycle control, SPDYA mediates cell survival during DNA damage through CDK2 activation 3. Mechanistically, SPDYA functions as a non-cyclin CDK activator, distinct from traditional cyclins 4. In neural stem cells, elevated SPDYA (also called SPY1) activates quiescent cells, promoting stemness and self-renewal while suppressing differentiation 5. During male meiosis, SPDYA interacts directly with SUN1 at the nuclear envelope to form telomere supramolecular architecture critical for homologous chromosome 2 and synapsis in prophase I 67. Disease relevance includes cancer contexts: SPDYA hypermethylation is a biomarker distinguishing hepatocellular carcinoma from normal liver tissue 8, and elevated SPDYA in glioblastoma correlates with increased oncogenic transformation risk 5. SPDYA also activates ERK1/2 independently of MEK, promoting tamoxifen resistance in breast cancer 9. Additionally, SPDYA appears as a fusion partner with ALK in select lung adenocarcinomas 10.